Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kasperkiewicz

Showing results (41-50 of 88) with videos related to

Pageof 9
Sort By:
The British Journal of Dermatology|August 25, 2025
Anti-p200 pemphigoidMichael Kasperkiewicz, Manuela Pigors, Maike M Holtsche, et al.
The Journal of Steroid Biochemistry and Molecular Biology|October 26, 2016
Autoimmunity to heat shock proteins and vitamin D status in patients with celiac disease without associated dermatitis herpetiformisStefan Tukaj, Anna Görög, Konrad Kleszczyński, et al.
Acta Dermato-Venereologica|April 1, 2015
Childhood epidermolysis bullosa acquisita with underlying coeliac diseaseMichael Kasperkiewicz, Irén Orosz, Dietrich Abeck, et al.
Journal of the American Academy of Dermatology|March 16, 2026
US expert opinions on the treatment of bullous pemphigoid based on guidelines from the European Academy of Dermatology and VenereologyMichael Kasperkiewicz, Mishek Thapa, Prince Adotama, et al.
Journal of the American Academy of Dermatology|June 24, 2024
Pemphigus following herpes simplex infection: A global comprehensive cohort studyMichael Kasperkiewicz, Binh T Ngo, Gema Hernandez, et al.
European Journal of Immunology|February 8, 2014
Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivoInessa Schwab, Sidonia Mihai, Michaela Seeling, et al.
Journal of Dermatological Science|July 17, 2017
CCL3/MIP1α represents a biomarker but not a mandatory cytokine for disease development in experimental epidermolysis bullosa acquisitaMichael Kasperkiewicz, Kathrin Kalies, Rene Pagel, et al.
Journal of the American Academy of Dermatology|June 7, 2011
Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patientsMichael Kasperkiewicz, Iakov Shimanovich, Ralf J Ludwig, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2023
Risk of de novo bullous pemphigoid and pemphigus following transplantation: A global wide-scale cohort studyMichael Kasperkiewicz, Jerzy W Kupiec-Weglinski, Binh T Ngo, et al.
Journal of the American Academy of Dermatology|November 23, 2024
Response to Baroukhian et al, "Pemphigus following herpes simplex infection: A global comprehensive cohort study"Philip Curman, Binh T Ngo, Gema Hernandez, et al.
Pageof 9

Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
The British Journal of Dermatology|August 25, 2025
Anti-p200 pemphigoidMichael Kasperkiewicz, Manuela Pigors, Maike M Holtsche, et al.
The Journal of Steroid Biochemistry and Molecular Biology|October 26, 2016
Autoimmunity to heat shock proteins and vitamin D status in patients with celiac disease without associated dermatitis herpetiformisStefan Tukaj, Anna Görög, Konrad Kleszczyński, et al.
Acta Dermato-Venereologica|April 1, 2015
Childhood epidermolysis bullosa acquisita with underlying coeliac diseaseMichael Kasperkiewicz, Irén Orosz, Dietrich Abeck, et al.
Journal of the American Academy of Dermatology|March 16, 2026
US expert opinions on the treatment of bullous pemphigoid based on guidelines from the European Academy of Dermatology and VenereologyMichael Kasperkiewicz, Mishek Thapa, Prince Adotama, et al.
Journal of the American Academy of Dermatology|June 24, 2024
Pemphigus following herpes simplex infection: A global comprehensive cohort studyMichael Kasperkiewicz, Binh T Ngo, Gema Hernandez, et al.
European Journal of Immunology|February 8, 2014
Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivoInessa Schwab, Sidonia Mihai, Michaela Seeling, et al.
Journal of Dermatological Science|July 17, 2017
CCL3/MIP1α represents a biomarker but not a mandatory cytokine for disease development in experimental epidermolysis bullosa acquisitaMichael Kasperkiewicz, Kathrin Kalies, Rene Pagel, et al.
Journal of the American Academy of Dermatology|June 7, 2011
Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patientsMichael Kasperkiewicz, Iakov Shimanovich, Ralf J Ludwig, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2023
Risk of de novo bullous pemphigoid and pemphigus following transplantation: A global wide-scale cohort studyMichael Kasperkiewicz, Jerzy W Kupiec-Weglinski, Binh T Ngo, et al.
Journal of the American Academy of Dermatology|November 23, 2024
Response to Baroukhian et al, "Pemphigus following herpes simplex infection: A global comprehensive cohort study"Philip Curman, Binh T Ngo, Gema Hernandez, et al.
Pageof 9